Your session is about to expire
← Back to Search
Cord Blood Transplant for Blood Cancers
Study Summary
This trial is studying how to make cord blood transplants more successful for adults with blood cancers.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a high-risk form of MDS or MPD.I have been diagnosed with myelofibrosis or another cancer that affects my bone marrow.My Non-Hodgkin lymphoma is at high risk of getting worse if not in remission.My brain or spinal cord cancer is still visible on scans.I had a stem cell transplant from my own cells within the last year.My organs are functioning well and I can do most activities.I have not taken any checkpoint inhibitors in the past year.I've had radiation that makes it unsafe to receive 400cGy total body irradiation.I do not have an active, uncontrolled infection at the time of transplantation.My BPDCN is currently in remission.I have received the specified prior treatment.I have had two stem cell transplants.My AML is in its first complete remission but at high risk of returning.My ALL is in its first complete remission but at high risk of returning.My health is too poor to undergo certain medical procedures.My acute leukemia is currently in remission.
- Group 1: Cord Blood Transplant
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate number of individuals taking part in this medical study?
"Accurately, according to clinicaltrials.gov, the trial is currently enrolling participants and was initially posted on May 22nd 2023 with a subsequent update taking place that same day. 54 patients are needed from 7 distinct medical centres."
Has the FDA sanctioned Cord Blood Transplant as a viable medical option?
"Given the Phase 2 status of this clinical trial, which implies limited safety data and no efficacy evidence, Power assigned a score of 2 to Cord Blood Transplant's overall safety."
For which demographics is this clinical investigation most advantageous?
"This clinical trial seeks a total of 54 participants with acute myeloid leukemia, ranging in age from 21 to 65 years old."
Are there currently any available openings for volunteers to participate in this research?
"Based on the information found on clinicaltrials.gov, this trial is actively enrolling subjects with an original post date of May 22nd 2023 and a most recent update dated for the same day."
Will individuals younger than 55 years-old be accepted into the research?
"Eligibility requirements for this clinical trial specify that the participants must be between 21 and 65 years old. In contrast, 534 trials are available to those below 18 and 1584 specifically target seniors age 65 or above."
How many health care facilities are conducting this trial?
"Seven medical centres are involved in this trial, among which three provide the participants with consent services. These include Memorial Sloan Kettering Monmouth (Consent only) based in Middletown, Memorial Sloan Kettering Bergen (Consent only) located at Montvale and finally Memorial Sloan Kettering Suffolk-Commack (Consent only), situated in Commack. The other four sites complete the list of participating institutions."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger